Startups channel feed

Not an an­ti-ag­ing play? Al­tos’ top sci­en­tist says they can pre­vent ag­ing in 20 years

4 years ago
R&D

Morn­ing­side re­veals its lat­est biotech ef­fort, seek­ing to tack­le wide range of in­flam­ma­to­ry dis­eases

4 years ago
Financing

Ex­clu­sive: ARCH and GV are build­ing a large start­up fo­cused on mi­to­chon­dr­i­al dis­eases

4 years ago

An AI biotech emerges from stealth promis­ing drugs 'on de­mand.' What will that look like, and is it even pos­si­ble?

4 years ago
Financing
AI

A dy­nam­ic on­col­o­gy duo team up on an I/O start­up fo­cused on next-gen sol­id tu­mor fight­ers

4 years ago
Financing

Flag­ship's lat­est boast? A start­up that will 'rev­o­lu­tion­ize treat­men­t' for 'nine­ty per­cent of hu­man ill­ness'

4 years ago

A new biotech out of Dana-Far­ber wants to join the long non-cod­ing RNA par­ty, with help from Bob Langer

4 years ago
Financing

With a new start­up, ARCH and Take­da wade in­to grow­ing search for a Swiss Army knife RNA drug

4 years ago
Financing

They made the first an­ti-VEGF drug 20+ years ago. Now two long­time part­ners have $65M to spot new eye drugs

4 years ago
Financing

With $200M in new cash, Syn­thego wants to be­come the man­u­fac­tur­ing bedrock for CRISPR. But where are its cus­tomers?

4 years ago
Financing
Manufacturing

No­var­tis vet is get­ting an­oth­er shot at mTOR fol­low­ing the im­plo­sion of a longevi­ty pi­o­neer

4 years ago
Deals

Some genes are too large to fit in­to AAV vec­tors. UCB, No­var­tis back $57M idea to de­liv­er them in parts in­stead

4 years ago
Financing
Cell/Gene Tx

Au­dentes’ for­mer CEO launch­es new biotech, with $155M for hives and in­flam­ma­tion

4 years ago
Financing

A new start­up sets course against a con­stel­la­tion of rare dis­eases with a first shot re­pur­pos­ing the SIRP path­way

4 years ago
Financing

AI start­up grabs $60M, un­veils plat­form aimed at drug dis­cov­ery's 'da­ta prob­lem'

4 years ago
Financing
AI

Scoop: Saman­tha Truex de­parts At­las to head $200M Or­biMed-backed im­munol­o­gy start­up

4 years ago
People

Roivant re­veals its newest 'vant,' try­ing to re­boot an Ei­sai blood can­cer pro­gram and out­flank Mer­ck, Bris­tol My­ers

4 years ago
Pharma

Scoop: Star neu­ro­sci­en­tist Asa Abe­liovich and Or­biMed are team­ing on yet an­oth­er biotech

4 years ago
People

Cell ther­a­py pi­o­neer Mark Frohlich takes the helm at tiny In­dap­ta as a suite of big-name back­ers jump aboard

4 years ago
People
Financing

A small Seat­tle biotech wants to take on Glax­o­SmithK­line's emerg­ing Shin­grix block­buster. RA Cap­i­tal is on board

4 years ago
Financing

Two Pan­dion vets jump back in­to the start­up world, this time us­ing ma­chine learn­ing to build bet­ter im­munol­o­gy drugs

4 years ago
Discovery

New Or­biMed-backed biotech aims to repli­cate Ver­tex's wild­ly suc­cess­ful cys­tic fi­bro­sis pills in oth­er dis­eases

4 years ago
Financing

Ex­clu­sive: ARCH-backed ex­er­cise-in-a-pill start­up qui­et­ly laid off half its staff, ‘ful­ly piv­ot­ed’ in Oc­to­ber

4 years ago

Take­da spins PhII rare dis­ease pro­grams in­to new start­up — send­ing 2 ex­ecs and some cash to get things go­ing

4 years ago
First page Previous page 42434445464748 Next page Last page
A service from the Financial Times